FY2022 EPS Estimates for Commonwealth Bank of Australia (OTCMKTS:CSLLY) Reduced by Analyst

Commonwealth Bank of Australia (OTCMKTS:CSLLY) – Analysts at Jefferies Financial Group dropped their FY2022 EPS estimates for shares of Commonwealth Bank of Australia in a report released on Thursday, June 25th. Jefferies Financial Group analyst D. Stanton now expects that the company will post earnings per share of $2.84 for the year, down from their prior estimate of $2.85. Jefferies Financial Group currently has a “Hold” rating on the stock.

CSLLY has been the subject of a number of other research reports. ValuEngine raised shares of Commonwealth Bank of Australia from a “sell” rating to a “hold” rating in a research note on Thursday, April 2nd. Zacks Investment Research raised Commonwealth Bank of Australia from a “sell” rating to a “hold” rating in a research report on Monday. Finally, Citigroup upgraded Commonwealth Bank of Australia from a “neutral” rating to a “buy” rating in a report on Thursday, May 28th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Commonwealth Bank of Australia currently has an average rating of “Hold” and a consensus target price of $110.00.

Shares of Commonwealth Bank of Australia stock opened at $99.84 on Monday. Commonwealth Bank of Australia has a 52 week low of $73.01 and a 52 week high of $114.40. The stock has a market cap of $90.31 billion, a PE ratio of 47.09 and a beta of 0.61. The company’s 50-day moving average price is $98.27 and its two-hundred day moving average price is $99.57.

About Commonwealth Bank of Australia

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders.

See Also: What is the Nikkei 225 index?    

Earnings History and Estimates for Commonwealth Bank of Australia (OTCMKTS:CSLLY)

Receive News & Ratings for Commonwealth Bank of Australia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Commonwealth Bank of Australia and related companies with MarketBeat.com's FREE daily email newsletter.